A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection

Not Applicable

Completed

• Conditions: HIV Infections

• Registration Number: NCT00002176
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma. To assess the long-term safety and tolerability of this combination therapy and the magnitude and duration of the effect of this therapy over CD4 cell counts.

Detailed Description

Not available

Study Timeline

• Study Start: 1997-05
• Study First Submitted: 1999-11-02
• Primary Completion: 2000-03
• Study Completion: 2000-03
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-13
• Last Update Posted: 2011-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Univ of California at San Francisco Gen Hosp; 🇺🇸 San Francisco, California, United States